Related Experiment Video

Updated: Dec 29, 2025

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

2.0K

Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI

Jujun Xue1, Cuiqing Wang2, Chengli Pan1

  • 1Department of Gerontological Neurology, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150001, P.R. China.

Experimental and Therapeutic Medicine
|February 4, 2020
PubMed

Insights

Dipeptidyl peptidase-4 (DPP-4) inhibitors improved cognitive function in elderly patients with type 2 diabetes and mild cognitive impairment. This treatment also helped lower blood sugar and reduce inflammation.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Geriatrics

Background:

  • Type 2 diabetes mellitus (T2DM) and post-stroke mild cognitive impairment (MCI) are prevalent in the elderly.
  • Both conditions pose significant challenges to patient health and quality of life.

Purpose of the Study:

  • To investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on glycemic control and cognitive function in elderly patients with T2DM and post-stroke MCI.
  • To explore the underlying mechanisms, including amyloid-beta (Aβ) aggregation and inflammatory responses.

Main Methods:

  • A comparative study involving 60 elderly patients with T2DM and post-stroke MCI.
  • Thirty patients received DPP-4 inhibitors (study group), and thirty received sulfonylurea (control group) for six months.
  • Evaluated blood sugar markers, cognitive scores, Aβ1-42/Aβ1-40 ratio, and inflammatory markers (TNF-α, IL-6, CRP).

Main Results:

  • Blood sugar markers improved in both groups, with no significant intergroup differences.
  • Cognitive ability scores significantly improved in the DPP-4 inhibitor group compared to the control group.
  • DPP-4 inhibitor treatment led to increased Aβ1-42/Aβ1-40 ratio and greater reductions in inflammatory markers (TNF-α, IL-6, CRP).

Conclusions:

  • DPP-4 inhibitors are effective in improving cognitive function in elderly patients with T2DM and post-stroke MCI.
  • The therapeutic mechanism may involve mitigating Aβ aggregation and reducing systemic inflammation.
  • DPP-4 inhibitors offer a promising therapeutic strategy for this patient population.
Keywords:
blood sugarcognitive impairmentefficacy

More Related Videos

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

13.0K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.8K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
497
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
175
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
147
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
147
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
175
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
156